There are currently 48 active clinical trials seeking participants for Prostate Adenocarcinoma research studies. The states with the highest number of trials for Prostate Adenocarcinoma participants are Illinois, California, Pennsylvania and Wisconsin.
Aspirin and Rintatolimod With or Without Interferon-alpha 2b in Treating Patients With Prostate Cancer Before Surgery
NCT03899987
Recruiting
This phase II trial studies how well enteric-coated (EC) aspirin and rintatolimod with or without interferon-alpha 2b work in treating patients with prostate cancer before surgery. EC Aspirin may help to keep the prostate cancer from coming back. Rintatolimod may stimulate the immune system and interfere with the ability of tumor cells to grow and spread. Interferon-alpha 2b may improve the body's natural response to infections and may slow tumor growth. It is not yet known how well rintatolimod... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Roswell Park Cancer Institute, Buffalo, New York
Conditions: Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8, Stage IIB Prostate Cancer AJCC v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8, Stage IIIA Prostate Cancer AJCC v8, Stage IIIB Prostate Cancer AJCC v8, Stage IIIC Prostate Cancer AJCC v8
Register for Updates
An Investigational Scan (68Ga-PSMA-11 PET) for the Imaging of Prostate Cancer
NCT04777071
Recruiting
This trial studies how well 68Ga-PSMA-11 PET scan works in imaging patients with prostate cancer. Diagnostic procedures, such as 68Ga-PSMA-11 PET may find and diagnose prostate cancer and improve monitoring of treatment response.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/14/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Biochemically Recurrent Prostate Carcinoma, Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma, Stage IV Prostate Cancer AJCC v8
Register for Updates
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
NCT05616650
Recruiting
Background: The current standard treatment of prostate cancer is either surgery or radiation. Typically, this includes either the removal or radiation of the whole prostate gland. Many people now seek out focal therapy options to decrease the side effects of treatment. Until now, several forms of physical destruction with heat (thermal ablation), cold (cryotherapy), sound waves (HIFU), laser (FLA), and electrical energy (IRE). A new type of radiation (SBRT) may be an effective way to cure men o... Read More
Gender:
MALE
Ages:
Between 18 years and 120 years
Trial Updated:
04/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Prostatic Neoplasms, Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
NCT05919329
Recruiting
This clinical trial investigates the change in prostate-specific membrane antigen (PSMA) expression in response to hormonal therapy in both, Castration Sensitive Prostate Cancer (CSPC) and Castration Resistant Prostate Cancer (CRPC), and whether this change in PSMA expression changes tumor staging after therapy initiation. Understanding these effects can help define the best timing to perform the PSMA positron emission tomography (PET) relative to the start of therapy.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/09/2025
Locations: OHSU Knight Cancer Institute, Portland, Oregon
Conditions: Castration Resistant Prostate Cancer, Castration Sensitive Prostate Cancer, Prostate Adenocarcinoma
Register for Updates
A Study on the Effects of Exercise Therapy on Signs of Prostate Cancer
NCT05751434
Recruiting
The purpose of this study is to find out the effects of exercise therapy on indicators of prostate cancer in people with low-risk prostate cancer who are on active surveillance. The exercise therapy in this study will be regular home-based walking sessions on a treadmill, and that therapy will be assigned by an exercise physiologist (a medical professional who studies how exercise affects the human body). Some participants in this study will have the assigned exercise therapy, and some participa... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: University of California, Los Angeles (Data and Specimen Analysis Only), Los Angeles, California +8 locations
Conditions: Prostate Cancer, Prostate Adenocarcinoma, Localized Prostate Carcinoma
Register for Updates
Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes
NCT05832086
Recruiting
This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking diet, or usual diet. All patients will receive standard of care treatment for their prostate cancer. The fasting mimicking diet will be consumed for 5 days per month for a total of 6 months and will be monitored by trained research dietitians. This study aims to examine the effects of a fasting mimi... Read More
Gender:
MALE
Ages:
All
Trial Updated:
04/01/2025
Locations: Beckman Research Institute of the City of Hope, Duarte, California +2 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients with Prostate Cancer on Active Surveillance
NCT03933670
Recruiting
This phase II trial studies the side how well hyperpolarized carbon C 13 pyruvate (HP C-13 pyruvate) magnetic resonance imaging (MRI) works in monitoring patients with prostate cancer on active surveillance who have not received treatment. Diagnostic procedures, such as MRI, may help visualize HP C-13 pyruvate uptake and breakdown in tumor cells.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/25/2025
Locations: University of California, San Francisco, San Francisco, California
Conditions: Prostate Adenocarcinoma, Prostate Cancer
Register for Updates
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
NCT05960578
Recruiting
This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer c... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/21/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Risk Stratified De-escalated Hormone Therapy with Radiation Therapy for the Treatment Prostate Cancer
NCT06369610
Recruiting
This phase II trial tests how well risk based de-escalated hormone therapy (i.e., fewer treatments) with radiation works in treating patients with prostate cancer. Androgen deprivation therapy (ADT), such as gonadotropin-releasing hormone analogs (LHRH) and abiraterone acetate (Zytiga), lower the amount of the male hormone, testosterone, made by the body. This may help kill or stop the growth of tumor cells that need testosterone to grow. Radiation therapy uses high energy x-rays, particles, or... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
03/19/2025
Locations: Mayo Clinic in Arizona, Scottsdale, Arizona
Conditions: Oligometastatic Prostate Carcinoma, Prostate Adenocarcinoma
Register for Updates
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084
Recruiting
This phase III trial uses the Decipher risk score to guide therapy selection. Decipher score is based on the activity of 22 genes in prostate tumor and may predict how likely it is for recurrent prostate cancer to spread (metastasize) to other parts of the body. Decipher score in this study is used for patient selection and the two variations of treatment to be studied: intensification for higher Decipher score or de-intensification for low Decipher score. Patients with higher Decipher risk scor... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/12/2025
Locations: University of Alabama at Birmingham Cancer Center, Birmingham, Alabama +550 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
PSMA PET Response Guided SabR in High Risk Pca
NCT06044857
Recruiting
Sequential cohort evaluation of ideal timing of imaging and treatment spacing to discern maximal PSMA (Prostate specific membrane antigen) PET (Positron Emission Tomography) response (PSMA-11 68Ga, Illucix) for adaptation of dominant intra-prostatic lesion tumor boost dose
Gender:
MALE
Ages:
Between 18 years and 99 years
Trial Updated:
03/11/2025
Locations: University of Texas Southwestern Medical Center, Dallas, Texas +1 locations
Conditions: Prostate Adenocarcinoma
Register for Updates
Neoadjuvant Lu-177-PSMA-617 in Patients With High Risk Localized Prostate Cancer Undergoing Radical Prostatectomy
NCT06798558
Recruiting
Male adults with a confirmed diagnosis of prostate adenocarcinoma who meet criteria for localized high risk prostate cancer according to the NCCN guidelines and who are eligible for prostatectomy will be invited to participate. Criteria for high-risk prostate cancer include patients with preoperative prostate biopsy score of Gleason 8 (GS8) (Grade group 4 \[GG4\]) or higher. Patients also need to have a positive PSMA scan on 68-Ga-PSMA-11 PET/CT scan.
Gender:
MALE
Ages:
18 years and above
Trial Updated:
03/07/2025
Locations: MedStar Washington Hospital Center, Washington, District of Columbia +2 locations
Conditions: Prostate Adenocarcinoma
Register for Updates